\ Welcome

The Citoxlab Group offers a comprehensive range of pre-clinical services for pharmaceutical, biotechnology, chemicals, cosmetics, medical devices and food companies worldwide. Our scientists and regulatory experts provide customized advice to help your development projects progress in the most effective way.

The Citoxlab Group has more than

1300 employees working in France, Canada, Denmark, Hungary and USA.

Proximity, the latest technologies and easy access to scientists, make Citoxlab your one-stop CRO for pre-clinical research. We offer maximum flexibility and expertise, major factors that guarantee the quality of your non-clinical programs.

Let’s build our future together !

\ News

  • 24/01/19

    14th Annual Biomarkers Congress

    February 21-22, 2019

    Manchester, UK

  • 24/01/19

    Society of Toxicology Annual Meeting

    March 10 – 14, 2019

    Baltimore, MD

  • 24/01/19


    April 1 – 5, 2019

    New Orleans, LA

  • 24/01/19


    April 28 – May 2, 2019

    Vancouver, BC

  • 26/11/18

    Webinar EOGRTS

    Watch a replay of our webinar EOGRTS


    An integrated evaluation of potential risks to development and reproduction is a key component in many marketing authorization applications.

    Citoxlab offers developmental and reproductive toxicology (DART) studies accepted by worldwide regulatory authorities for the safety testing of pharmaceuticals, biologics, gene-therapy products, food additives, chemicals, agrochemicals, veterinary medicines and consumer products. Studies cover the whole scope of developmental and reproductive toxicology, testing for potential effects on fertility, through embryo‑fetal, post-natal and juvenile stages, up to the second generation.

    Specialized evaluations can be combined in your DART studies, such as neurobehavioral testing, sperm/oestrous cycle analyses, developmental immunotoxicology, neuro-histomorphometry, skeletal development (X-ray, DXA, pQCT and microCT), genomics and extended one-generation reproductive toxicity study (EOGRTS).

    By the way, since its adoption in 2011, the EOGRTS (OECD 443 test guideline) has become a key milestone in the assessment of potential effects of chemicals on fertility and development, including effects on the developing nervous and immune systems.

    Thanks to a solid expertise in Developmental and Reproductive Toxicology, Citoxlab has the experience and know-how required for managing such a complex study and has already built a robust Historical Control Dataset.

    In this Webinar, using experience gained during the conduct and reporting of EOGRTS, Citoxlab will present the lessons learned and discuss the development and benefits of conducting such a study, with special focus on the challenges faced both by registrants and CROs in meeting the volume of demand for those in the coming years.

    Speakers and moderator experts

    Judit Hargitai David Esdaile Glyn Horner
    Associate Scientific Director specialized in the scientific management of long-term studies Director of Science and Regulatory Affairs at Citoxlab Hungary Business Development Director
  • 01/11/16

    European Teratology Society

    September 10 – 13, 2018

    Berlin, Germany